Edwards Lifesciences Logo
US28176E1082
936853
EW

Edwards Lifesciences

Loading quotes...

Forecast

The analysts' average price target is €98.66 (+1.98%). The median is €99.84 (+3.20%).

Buy
  34
Hold
  15
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • CMS guideline on TAVR reimbursement strengthens Edwards Lifesciences

    US agency CMS has published a final national reimbursement guideline for TAVR that also provides reimbursement for asymptomatic aortic stenosis, thereby strengthening the TAVR market. Stifel views the decision as positive for Edwards Lifesciences and expects it to support the long-term revenue growth forecast of over 10%. The guideline retains case volume requirements and the role of the heart team including cardiac surgeons, but allows asynchronous chart review and requires only a single TAVR operator in the room, which increases procedural efficiency. CMS also announced a national review of reimbursement for TAVR in aortic regurgitation, expected to conclude on June 8, 2027. » More on de.investing.com


  • Edwards Lifesciences noted as leader in TAVR growth by Aristotle Value fund

    Aristotle Capital's Value Equity Fund highlighted Edwards Lifesciences for its leadership in transcatheter aortic valve replacement (TAVR) and structural heart therapies, citing the procedure's role in expanding patient eligibility and market adoption. The fund referenced Edwards' market position and recent stock range, with shares around $90.78 and a market cap near $51.8 billion. The mention came in the fund's Q2 2026 letter, which contrasted its own underperformance versus AI-driven index gains while still listing Edwards among notable holdings. 68 hedge funds held Edwards at the end of Q1 2026, up from 64 the prior quarter. » More on finance.yahoo.com


  • Edwards Lifesciences reaches new 52-week high at 92.94 USD

    Shares of Edwards Lifesciences rose to a 52-week high of 92.94 USD and are currently trading just below that level; year-to-date the stock is up about 20.09%. The company trades at a P/E ratio of 50.01 and is considered overvalued by InvestingPro. At the New York Valves 2026 conference Edwards presented data from the PROGRESS study on TAVR, and the U.S. government proposed a National Coverage Decision memorandum for TAVR, which analysts view positively. Leerink reiterated "Market Perform" with a price target of 87 USD, TD Cowen raised its target to 104 USD; Theodora Mistras was also appointed as the new chief financial officer. » More on de.investing.com


  • Edwards Lifesciences hits 52-week high of $87.89 after strong Q1

    Edwards Lifesciences shares rose to a 52-week high of $87.89 and are currently trading at $87.91. In Q1 2026 the company reported revenue of $1.65bn (+12.7% currency‑adjusted) and earnings per share of $0.78, both above expectations. Analysts revised their views: several firms raised price targets and ratings, while InvestingPro rates the stock as overvalued and several earnings forecasts were revised down. Theodora Mistras was also appointed as the new chief financial officer effective late May. » More on de.investing.com


  • Edwards Lifesciences names Doretta Mistras chief financial officer

    Edwards Lifesciences has appointed Doretta Mistras as corporate vice president and CFO; she will assume the role at the end of May and succeeds Scott Ullem, who had already announced his departure and will remain as a strategic adviser during the transition. Mistras joins from Viatris, where she had served since March 2024 as CFO of the global finance organization and previously held leadership roles in healthcare investment banking at Citigroup and Goldman Sachs. The company has a market capitalization of $48 billion, revenue growth of 14% and a gross profit margin of nearly 78%; the stock is trading near its 52-week high. Analysts have recently cut their earnings forecasts (13 analysts), giving the CFO change added significance. » More on de.investing.com

Financials

In the last quarter, Edwards Lifesciences had revenue of €1.51bn and net profit of €271.48m
(EUR) September 2026
YoY
Revenue 1.51bn 14.44%
Gross profit 1.19bn 15.31%
Net profit 271.48m 9.44%
EBITDA 360.29m 9.08%

Fundamentals

Metric Value
Market capitalization
€55.21bn
Number of shares
575m
52-week high/low
€96.90 - €67.76
Dividends No
Beta
0.85
P/E ratio
59.77
PEG ratio
-2.49
P/B ratio
5.61
P/S ratio
9.11

Company profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Name
Edwards Lifesciences
CEO
Bernard J. Zovighian
Headquarters Irvine, ca
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
27/03/2000
Employees 16,000

Ticker symbols

Exchange Symbol
NYSE
EW
XETRA
EWL.DE
Frankfurt
EWL.F
Düsseldorf
EWL.DU
Milan
1EW.MI
London
0REN.L
SIX
EW.SW
München
EWL.MU
Wien
EWLS.VI
🍪

Parqet  uses cookies. Learn more